FIELD: medicine.
SUBSTANCE: invention is related to a compound represented by the formula
and its pharmaceutically acceptable salt. The invention is also related to a complex and a co-crystal containing said compound and fumaric acid in a 1:1 molar ratio, with an X-ray powder diffraction pattern having peaks at diffraction angles (2θ): 9.5±0.2°, 10.9±0.2°, 18.6±0.2°, 23.5±0.2° and 24.6±0.2°.
EFFECT: obtaining a new compound, as well as a complex and a co-crystal based on it with fumaric acid, which can be used in medicine for the treatment and/or prevention of a disease associated with coronavirus 3CL proteases.
12 cl, 13 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHILLYRIN AND ITS DERIVATIVES FOR SUPPRESSION OF THE 3CLPRO PROTEIN AND FIGHTING THE COVID-19 VIRUS | 2021 |
|
RU2804307C1 |
| METHOD FOR PREPARING A THIO DERIVATIVE OF PYRROLIDINE-2,5-DIONE WITH A QUINAZOLINE FRAGMENT | 2021 |
|
RU2807057C2 |
| SOLID FORMS OF TTK INHIBITOR | 2017 |
|
RU2753905C2 |
| NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2786722C1 |
| NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2820150C2 |
| LIPOSOMAL COMPOSITION OF 5-CHLOROPYRIDIN-3-IL-1H-INDOL-4-CARBOXYLATE AS A POTENTIAL EMERGENCY PREVENTION AND TREATMENT OF CORONAVIRUS INFECTIONS | 2023 |
|
RU2810261C1 |
| PANDEMIC-PROTECTIVE MOBILE SPITTOON | 2020 |
|
RU2754883C1 |
| SOLUBLE RECOMBINANT PLASMID PET-GST-3CL ENSURING SYNTHESIS OF 3CL SARS-COV-2 PROTEASE IN E. COLI CELLS | 2022 |
|
RU2792132C1 |
| APPLICATION OF A DERIVATIVE OF 1,3,5-TRIAZINE-2,4-DIAMINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780249C1 |
| SET OF SYNTHETIC OLIGONUCLEOTIDES FOR THE DETECTION OF RNA VIRUSES SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1 OF THE CORONAVIRIDAE FAMILY BY LOOP ISOTHERMAL AMPLIFICATION (LIA) | 2021 |
|
RU2775481C1 |
